The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.

[1]  E. Sacco,et al.  Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure , 2022, Cardiovascular Diabetology.

[2]  F. Berenbaum,et al.  Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis , 2022, Scientific Reports.

[3]  E. Duh,et al.  Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy , 2021, JCI insight.

[4]  C. Mandarim-de-Lacerda,et al.  Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist , 2021, International Journal of Obesity.

[5]  V. Guarnotta,et al.  Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus. , 2021, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[6]  J. Halcox,et al.  Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials , 2021, Diabetes, obesity & metabolism.

[7]  M. Manns,et al.  Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH , 2021, Biomedicines.

[8]  F. Servant,et al.  Liraglutide targets the gut microbiota and the intestinal immune system to regulate insulin secretion , 2021, Acta Diabetologica.

[9]  G. Zuccotti,et al.  Anti-inflammatory effects of diet and caloric restriction in metabolic syndrome , 2021, Journal of Endocrinological Investigation.

[10]  H. Kaneto,et al.  Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better , 2021, Scientific Reports.

[11]  Modupeore O. Adetunji,et al.  GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension , 2020, Cell reports.

[12]  M. Nauck,et al.  GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art , 2020, Molecular metabolism.

[13]  G. Heeba,et al.  Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats. , 2020, Life sciences.

[14]  P. Moreira,et al.  Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation , 2020, International journal of molecular sciences.

[15]  H. Jun,et al.  Preventive Effects of Dulaglutide on Disuse Muscle Atrophy Through Inhibition of Inflammation and Apoptosis by Induction of Hsp72 Expression , 2020, Frontiers in Pharmacology.

[16]  M. Maleki,et al.  Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes. , 2019, Life sciences.

[17]  Yuge Wang,et al.  The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke , 2019, Journal of Neuroinflammation.

[18]  M. Pollheimer,et al.  Glucagon Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T Cell Proliferation. , 2019, The American journal of pathology.

[19]  Xin Guo,et al.  Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. , 2019, International immunopharmacology.

[20]  L. Qing,et al.  Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice , 2019, Endocrine.

[21]  J. Rosenstock,et al.  Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial , 2019, Diabetes Care.

[22]  L. V. Van Gaal,et al.  Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity , 2019, Alimentary pharmacology & therapeutics.

[23]  Ming-Wei Lin,et al.  Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System , 2019, International journal of molecular sciences.

[24]  A. Rosato,et al.  Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway , 2019, Diabetes.

[25]  Yan-wen Shu,et al.  Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model , 2019, Transplantation.

[26]  J. Gong,et al.  Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway. , 2019, Biochemical and biophysical research communications.

[27]  Dimitris Tousoulis,et al.  The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives , 2018, European cardiology.

[28]  P. Newsholme,et al.  Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function , 2018, Front. Endocrinol..

[29]  J. Hecksher-Sørensen,et al.  The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways , 2018, JACC. Basic to translational science.

[30]  S. Heegaard,et al.  Glucagon‐like peptide‐1 receptor expression in the human eye , 2018, Diabetes, obesity & metabolism.

[31]  D. Drucker.  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.

[32]  H. Kitaura,et al.  The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-α Expression in Macrophages , 2018, Journal of immunology research.

[33]  O. Belton,et al.  Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis , 2017, Cardiovascular Diabetology.

[34]  H. Itoh,et al.  GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice. , 2017, Journal of diabetes and its complications.

[35]  K. Okumura,et al.  Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress. , 2017, Atherosclerosis.

[36]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[37]  S. Martínez-Hervás,et al.  The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype , 2017, Diabetologia.

[38]  T. Hansen,et al.  Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub‐analysis of a randomized, placebo‐controlled, double‐blind, crossover trial , 2017, Diabetes, obesity & metabolism.

[39]  P. O'Byrne,et al.  Glucagon‐like peptide‐1 receptor expression on human eosinophils and its regulation of eosinophil activation , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  L. Nielsen,et al.  Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice , 2016, PloS one.

[41]  S. Dal,et al.  Improvement of islet graft function using liraglutide is correlated with its anti‐inflammatory properties , 2016, British journal of pharmacology.

[42]  Katherine B. LeClair,et al.  iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy. , 2016, Cell metabolism.

[43]  I. Hirsch,et al.  Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial , 2016, Diabetes Care.

[44]  D. Drucker.  The Cardiovascular Biology of Glucagon-like Peptide-1. , 2016, Cell metabolism.

[45]  H. Jun,et al.  Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control , 2016, Mediators of inflammation.

[46]  B. Okopień,et al.  Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner , 2016, Pharmacological reports : PR.

[47]  A. Shimatsu,et al.  Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects. , 2016, Metabolism: clinical and experimental.

[48]  M. Tate,et al.  Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages , 2015, Basic Research in Cardiology.

[49]  S. Bolkent,et al.  Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice , 2015, Growth factors.

[50]  M. Surette,et al.  GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R , 2015, Diabetes.

[51]  Youyou Zhao,et al.  Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix , 2015, Basic Research in Cardiology.

[52]  M. Banach,et al.  Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. , 2015, The Journal of clinical endocrinology and metabolism.

[53]  Marina T. DiStefano,et al.  IL-1 Signaling in Obesity-Induced Hepatic Lipogenesis and Steatosis , 2014, PloS one.

[54]  R. Testa,et al.  Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes , 2014, Diabetes Care.

[55]  D. Drucker,et al.  Cardiovascular actions of incretin-based therapies. , 2014, Circulation research.

[56]  T. Hirano,et al.  A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis , 2014, Peptides.

[57]  L. Lynch,et al.  Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus , 2014, Diabetologia.

[58]  K. Docherty,et al.  Cell therapy for type 1 diabetes , 2014, QJM : monthly journal of the Association of Physicians.

[59]  J. Romijn,et al.  Exendin‐4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration , 2014, British journal of pharmacology.

[60]  L. Bardram,et al.  GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. , 2014, Endocrinology.

[61]  D. Giugliano,et al.  Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes , 2013, Diabetes Care.

[62]  K. Cheung,et al.  Anti‐inflammatory effects of exendin‐4, a glucagon‐like peptide‐1 analog, on human peripheral lymphocytes in patients with type 2 diabetes , 2013, Journal of diabetes investigation.

[63]  Yukio Fujiwara,et al.  Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. , 2012, Biochemical and biophysical research communications.

[64]  S. Ha,et al.  Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes , 2012, Diabetologia.

[65]  C. Ricordi,et al.  Anti-Inflammatory Properties of Exenatide in Human Pancreatic Islets , 2012, Cell transplantation.

[66]  D. Doherty,et al.  Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis , 2011, Diabetologia.

[67]  S. Miyamoto,et al.  Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes , 2011, Diabetologia.

[68]  V. Hombach,et al.  Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes , 2010, Cellular and Molecular Life Sciences.

[69]  R. Kawamori,et al.  Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.

[70]  K. Siminovitch,et al.  Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells , 2010, Diabetologia.

[71]  R. Tisch,et al.  Immunotherapy of type 1 diabetes , 2008, Archivum Immunologiae et Therapiae Experimentalis.

[72]  G. Waeber,et al.  Exendin-4 Protects β-Cells From Interleukin-1β–Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase Pathway , 2008, Diabetes.

[73]  D. Drucker,et al.  Exendin-4 modulates diabetes onset in nonobese diabetic mice. , 2008, Endocrinology.

[74]  J. Nadler,et al.  Inflammatory mechanisms of diabetic complications , 2007, Current diabetes reports.

[75]  Dafang Wang,et al.  Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment , 2020 .

[76]  P. Dandona,et al.  Exenatide exerts a potent antiinflammatory effect. , 2012, The Journal of clinical endocrinology and metabolism.